Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment

Masato Shikata; Kenji Ashida; Yuka Goto; Ayako Nagayama; Shimpei Iwata; Mamiko Yano; Nao Hasuzawa; Kento Hara; Kazutoshi Mawatari; Kiyohiko Sakata; Munehisa Tsuruta; Nobuhiko Wada; Masatoshi Nomura

doi:10.1002/ccr3.3230

Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment

Clin Case Rep. 2020 Aug 13;8(12):2613-2618. doi: 10.1002/ccr3.3230. eCollection 2020 Dec.

Affiliations

¹ Division of Endocrinology and Metabolism Department of Internal Medicine Kurume University School of Medicine Fukuoka Japan.
² Division of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Fukuoka Japan.
³ Department of Neurosurgery Kurume University School of Medicine Fukuoka Japan.

Abstract

Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type-5 stimulation. GLP-1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.

Keywords: Cushing's disease; diabetes mellitus; glucagon‐like peptide‐1 receptor agonist; pasireotide; sodium‐glucose cotransporter 2 inhibitor.

Publication types

Case Reports